We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: April 1, 2008
Last Update Posted: May 17, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
National Cancer Institute (NCI)
Information provided by:
Esanex Inc.
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.

Condition Intervention Phase
Solid Tumor Malignancy Lymphoid Malignancy (Lymphoma and CLL) Leukemia Lymphoma Drug: SNX-5422 Mesylate Hsp90 inhibitor Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1 Study Of SNX-5422 Mesylate In Adults With Refractory Solid Tumor Malignancies And Lymphomas

Resource links provided by NLM:

Further study details as provided by Esanex Inc.:

Primary Outcome Measures:
  • MTD, safety and toxicity [ Time Frame: continuous ]

Secondary Outcome Measures:
  • pharmacokinetic profile of SNX-5422 [ Time Frame: first cycle ]
  • tumor response measured by X-rays or scans [ Time Frame: after every 2 cycles ]

Enrollment: 32
Study Start Date: March 2008
Study Completion Date: September 2010
Primary Completion Date: September 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single Arm Drug: SNX-5422 Mesylate Hsp90 inhibitor
dose escalated, tablets twice a week; undetermined duration until disease progression


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Solid tumors or lymphoid malignancies refractory to standard therapy
  • measurable disease
  • recovery to Grade < 1 toxicity due to prior adverse event or chemotherapy
  • no chemotherapy within 4 weeks of entering study
  • Age > 18 years
  • Karnofsy >= 60%
  • Life expectancy > 3 months
  • normal or adequate organ and marrow function

Exclusion Criteria:

  • receiving other investigational agents
  • brain metastases
  • uncontrolled medical illness
  • HIV+ receiving combination antiretroviral therapy
  • significant GI disease
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00647764

United States, Maryland
Pfizer Investigational Site
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
Esanex Inc.
National Cancer Institute (NCI)
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00647764     History of Changes
Other Study ID Numbers: B1311003
First Submitted: March 27, 2008
First Posted: April 1, 2008
Last Update Posted: May 17, 2012
Last Verified: May 2012

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases